Template:Dihydroergotamine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Dihydroergotamine|{{fontcolor|#6C7B8B|Dihydroergotamine}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Dihydroergotamine|{{fontcolor|#6C7B8B|Dihydroergotamine}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | MIGRANAL (dihydroergotamine mesylate) spray<sup>®</sup> FDA Package Insert | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine indications and usage|Indications and Usage]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine dosage and administration|Dosage and Administration]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine dosage forms and strengths|Dosage Forms and Strengths]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine contraindications|Contraindications]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine warnings and precautions|Warnings and Precautions]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine adverse reactions|Adverse Reactions]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine drug interactions|Drug Interactions]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine use in specific populations|Use in Specific Populations]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine overdosage|Overdosage]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine description|Description]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine clinical pharmacology|Clinical Pharmacology]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine nonclinical toxicology|Nonclinical Toxicology]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine clinical studies|Clinical Studies]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine how supplied storage and handling|How Supplied/Storage and Handling]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine patient counseling information|Patient Counseling Information]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine labels and packages|Labels and Packages]] | |||
|- | |||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Dihydroergotamine | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov] | |||
|- | |||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Dihydroergotamine|{{fontcolor|#6C7B8B|Dihydroergotamine}}]]''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | D.H.E. 45 (dihydroergotamine mesylate) injection, solution<sup>®</sup> FDA Package Insert | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Dihydroergotamine indications and usage|Indications and Usage]] | ||
Latest revision as of 22:06, 11 February 2014
| Dihydroergotamine |
|---|
| MIGRANAL (dihydroergotamine mesylate) spray® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Dihydroergotamine |
| ClinicalTrials.gov |
| Dihydroergotamine |
| D.H.E. 45 (dihydroergotamine mesylate) injection, solution® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Dihydroergotamine |
| ClinicalTrials.gov |